Mao Yu, Hao Jian, Jin Zi-Qi, Niu Yang-Yang, Yang Xue, Liu Dan, Cao Rui, Wu Xiong-Zhi
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.
Tianjin Medical University, Tianjin, 300070, China.
Oncotarget. 2017 Apr 18;8(16):27007-27021. doi: 10.18632/oncotarget.15351.
Chinese Herbal Medicine (CHM) plays a significant role in breast cancer treatment. We conduct the study to ascertain the relative molecular targets of effective Chinese herbs in treating stage IV breast cancer.Survival benefit of CHM was verified by Kaplan-Meier method and Cox regression analysis. A bivariate correlation analysis was used to find and establish the effect of herbs in complex CHM formulas. A network pharmacological approach was adopted to explore the potential mechanisms of CHM.Patients in the CHM group had a median survival time of 55 months, which was longer than the 23 months of patients in the non-CHM group. Cox regression analysis indicated that CHM was an independent protective factor. Correlation analysis showed that 10 herbs were strongly correlated with favorable survival outcomes (P<0.01). Bioinformatics analyses suggested that the 10 herbs might achieve anti-breast cancer activity primarily through inhibiting HSP90, ERα and TOP-II related pathways.
中药在乳腺癌治疗中发挥着重要作用。我们开展本研究以确定治疗IV期乳腺癌的有效中药的相关分子靶点。通过Kaplan-Meier法和Cox回归分析验证了中药的生存获益。采用双变量相关性分析来发现并确定中药复方中各味中药的作用。采用网络药理学方法探索中药的潜在作用机制。中药组患者的中位生存时间为55个月，长于非中药组患者的23个月。Cox回归分析表明，中药是一个独立的保护因素。相关性分析显示，10味中药与良好的生存结局密切相关（P<0.01）。生物信息学分析表明，这10味中药可能主要通过抑制HSP90、ERα和TOP-II相关通路来实现抗乳腺癌活性。
